Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 iito 650x76px
Financing › Details

Frequency Therapeutics–SEVERAL: investment, 201910 IPO $84m+$12.6m with 6m+900k shares common stock at $14/share at Nasdaq Global Select Market

 

Period Period 2019-10-03
Region Region United States (USA)
  Predecessor Frequency Therapeutics–SEVERAL: investment, 201907 financing round Series C $62m led by Perceptive Advisors
Organisation Money taker Frequency Therapeutics Inc. (Nasdaq: FREQ)
Products Product FX-322 PCA treatment (Frequency Therapeutics)
  Product 2 investment banking
     

Frequency Therapeutics, Inc.. (10/2/19). "Press Release: Frequency Therapeutics Announces Pricing of Initial Public Offering". Woburn, MA.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $84.0 million, before deducting underwriting discounts and commissions. All of the common stock is being offered by Frequency. In addition, Frequency has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. Frequency’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 3, 2019 under the ticker symbol “FREQ.” The offering is expected to close on October 7, 2019, subject to customary closing conditions.

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.

A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 1-866-803-9204, or via email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, via telephone: (833) 297-2926, or via email: PostSaleManualRequests@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.


About Frequency Therapeutics

Headquartered in Woburn, Mass., Frequency Therapeutics is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Frequency’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapeutics. The company’s lead product candidate, FX-322, is in clinical development and is designed to regenerate auditory hair cells to restore hearing function in patients with sensorineural hearing loss, the most common form of hearing loss. The company is also evaluating its PCA approach in additional diseases, including multiple sclerosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191002005895/en/

Source: Frequency Therapeutics, Inc.


Media Contact:
Michael Lampe or
Beth Kramli
Scient Public Relations
Tel: 484-575-5040
Email: FrequencyTx@scientpr.com

Investor Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
Tel: 617-914-0008
Email: ctanzi@kendallIR.com

   
Record changed: 2019-10-05

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Frequency Therapeutics Inc. (Nasdaq: FREQ)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 iito 650x76px




» top